Press release
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future.There has been a continuous rise in the market for therapeutic monoclonal in recent years. In 2012, there were more than 25 monoclonals in US and the EU. Currently, there are about 10 monoclonals which have already achieved category of "blockbuster", that is they are widely used medications that have been able to generate profits of more than US$ 1 Billion (each) to companies that market them. It has been estimated that in 2012, the global sales of antibody-based therapeutic products was around US$ 55 Billion.
Download Report:
http://www.pnspharma.com/buy-report.php?reporttitle=Global-Monoclonal-Antibodies-Pipeline-Analysis
“Global Monoclonal Antibodies Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various Monoclonal Antibodies based drugs being developed for the treatment of multiple diseases. Research report covers all Monoclonal Antibodies based being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Monoclonal Antibodies market based upon development process.
Following parameters for each orphan designated drug profile in development phase are covered in “Global Monoclonal Antibodies Pipeline Analysis” research report:
• Drug Profile Overview
• Alternate Names for Drug
• Active Indication
• Phase of Development
• Mechanism of Action
• Brand Name
• Patent Information
• Orphan Designation by Indication, Country & Organisation
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class
• ATC Codes
Global Monoclonal Antibodies Pipeline by Clinical Phase:
• Research: 117
• Preclinical: 426
• Clinical: 11
• Phase-0: 1
• Phase-I: 183
• Phase-I/II: 35
• Phase-II: 159
• Phase-II/III: 7
• Phase-III: 64
• Preregistration: 4
• Registered: 2
• Marketed: 56
• Unknown: 7
For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com
Recent Publication
* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022
PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.
Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Monoclonal Antibodies Pipeline Analysis here
News-ID: 603438 • Views: …
More Releases from PNS Pharma
Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight:
o Global Gene Therapy Market Opportunity: > US$ 8 Billion
o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials
o Commercially Available Gene Therapies: 11
o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials
o Cancer Accounts For 50% of Global Gene Therapy Trials
Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026
Over the years, gene therapy has been highly responsible for decreasing the mortality rate…
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
More Releases for Phase
Three-Phase Hybrid Inverter Market Efficient and Reliable Power Conversion Solut …
Global Three-Phase Hybrid Inverter Market Overview:
The Three-Phase Hybrid Inverter market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Three-Phase Hybrid Inverter market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and globalization. This growth…
Clinical Trials by Phase (Phase I, Phase II, Phase III, Phase IV) Market Forecas …
A clinical trial is a research study, where a group of people is given a test or treatment. Clinical trials study the safety and efficacy of tests and treatments. If the test or treatment is safe and meets regulatory requirements, then it is approved as a standard of care.
Download Sample Copy at https://www.theinsightpartners.com/sample/TIPRE00006203/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
IQVIA
Parexel International Corporation
Charles River Laboratories
ICON plc
SGS SA
Chiltern International Ltd
Syneos Health
PRA Health Sciences
Wuxi AppTec Inc
Pharmaceutical Product Development,…
Digital Phase Shifters Market
Digital Phase Shifters Market A recently identified vacuum in the literature about the creation of digital phase shifters for modern communication systems is attempted to be filled in the book Design of Digital Phase Shifters for Multipurpose Communication Systems. By significantly reducing RF power consumption and improving noise immunity, directed beams enhance the development of new-generation mobile communication systems. In this regard, digital phase shifters in particular, which are part…
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other…
Power Metering Market Information by type (smart, digital, analog), by phase (si …
Power Metering Market Information by type (smart, digital, analog), by phase (single phase, three phase) by application (residential, commercial and industrial) and Region - Forecast to 2022
The report for Global Power Metering Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and…
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027.
HIV Vaccines Market - Segmentation
The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region.
Antibiotics have been segmented into dicloxacillin,…